1. Volume 14, Issue 9, Pages 893-900 (August 2013)
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial 
Dr David I Quinn, FRACP, Catherine M Tangen, DrPH, Prof Maha Hussain, MD, Prof Primo N Lara, MD, Amir Goldkorn, MD, Carol M Moinpour, PhD, Mark G Garzotto, MD, Philip C Mack, PhD, Prof Michael A Carducci, MD, J Paul Monk, MD, Przemyslaw W Twardowski, Peter J Van Veldhuizen, MD, Neeraj Agarwal, MD, Prof Celestia S Higano, MD, Nicholas J Vogelzang, MD, Prof Ian M Thompson, MD 
The Lancet Oncology 
Volume 14, Issue 9, Pages (August 2013)
DOI: /S (13)
Copyright © 2013 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

3. Figure 2 Kaplan-Meier curves of composite progression-free survival
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

4. Figure 3 Kaplan-Meier curves of overall survival
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions